Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Yi, Shan-Yonga; * | Ruan, Jingb | Zhao, Linga | Ke, Yanga | Li, Xiang-Nanc; *
Affiliations: [a] Department of Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China | [b] Department of Optometry, College of Optometry of Tianjin Medical University, Tianjin, China | [c] Department of Chest Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Correspondence: [*] Corresponding authors: Shan-Yong Yi, Department of Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, Henan, China. E-mail: yisy2001@163.com; Xiang-Nan Li, Department of Chest Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China. Tel.: +86 371 67690445; Fax: +86 371 67690445; E-mail: wintersweet66@163.com. E-mail: yisy2001@163.com; Xiang-Nan Li, Department of Chest Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China. Tel.: +86 371 67690445; Fax: +86 371 67690445; E-mail: wintersweet66@163.com.
Abstract: Recently, compelling evidence shows that cancer stem-like cells (CSLC) are thought to be critical for initiation and propagation of many types of cancers. Most of CSLC are dependent upon the vascular microenvironments that promote their long-term growth and self-renewal. However, it is not known if when we disrupted their vascular microenvironments, CSLC would be eliminated. Considering these possibilities, we have investigated the influence of different chemotherapy regimens on the CSLC population of hepatocarcinoma xenografts model. The mouse models of hepatocarcinoma were treated with different therapeutic regimens: low-dose metronomic (LDM) regimens, combination therapies of Bolus dose and low-dose metronomic regimens, for the purpose of comparison, a conventional cytotoxic schedule of maximum tolerated dose (MTD) chemotherapy using gemcitabine (GEM). All therapies produced a significant tumor growth delay. LDM GEM and Bolus+LDM GEM significantly reduced the tumor spheres, whereas MTD GEM had no effect on the tumor spheres. Furthermore, Bolus+LDM GEM could more significantly decrease both the population of CSLC and the levels of viable endothelial progenitor cells (EPC). Overall, our data indicate that Bolus+LDM GEM is a potent treatment regimen for inhibiting angiogenesis, attacking the tumor vascular microenvironments, and decreasing the population of CSLC. Targeting the unique microenvironment of CSLC may be the key to effective cancer therapy, and shows great promise for the clinical practice.
Keywords: Metronomic chemotherapy, gemcitabine, tumor vascular microenvironment, cancer stem-like cells, hepatocarcinoma
DOI: 10.3233/CBM-140419
Journal: Cancer Biomarkers, vol. 14, no. 6, pp. 427-433, 2014
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl